pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

320 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1602Endpoints1254BioSpace587Fierce Biotech583BioPharma Dive474raps199onclive165fda recalls104
therapy area
allOncology10822Rare Disease2804Immunology2566Cardiology2301Pulmonology1910Hematology1907Vaccines1658Psychiatry & CNS
  • Takeda advances gene therapy, UK cancer biotech raises $83M, and new blood test may guide Wegovy use
    A Cleveland‑based biotech announced that a previously halted gene therapy program has been revived, offering a potential new option for patients as the company pursues additional studies. Takeda r…
    Endpoints · 5mo agoNeutral↗ source
  • Supreme Court temporarily restores broad access to abortion pill mifepristone
    The Supreme Court issued an order on Monday that temporarily reinstates wide availability of the abortion medication mifepristone. The order follows a federal appeals court decision that had threat…
    STAT · 5mo agoRegulatoryNeutral↗ source
← prev
page 13 of 13
next →
fda medwatch95
globenewswire health73
fda press55
1111
Ophthalmology882
Endocrinology & Metabolism699
Pain676
Nephrology675
  • Latus Bio raises $97 million to advance gene therapies for Huntington’s and Batten disease
    Latus Bio announced closing a $97 million Series A round, including a $43 million extension to a prior $54 million raise. Funding was led by 8VC and included eight other investors such as DCVC Bio…
    BioPharma Dive · 5mo agoDealPositive↗ source
  • Latus Bio secures $42 million to launch Huntington’s disease gene therapy trial
    Biotech startup Latus Bio announced it has raised $42 million to fund its first clinical trials, including a gene‑therapy program aimed at Huntington’s disease. The capital will be used to seek FDA…
    STAT · 5mo agoDealPositive↗ source
  • Biotech sees rise of lean startups backed by large funding and Chinese assets
    A new wave of biotech companies is emerging that prioritises lean organizational structures over extensive early‑stage research programs. These firms are being launched with modest employee counts…
    Endpoints · 5mo agoNeutral↗ source
  • Experts question the validity of blue zones concept amid new genetic study
    The opinion piece by medical journalist Shelley Wood and cardiologist Eric Topol examines growing doubts about the “blue zones” idea, which originally described a handful of Sardinian villages note…
    STAT · 5mo agoNeutral↗ source
  • Bristol Myers shows modest revenue rise, Biogen beats forecasts, Regeneron outlook remains uncertain
    BioPharma Dive highlighted the latest quarterly earnings from three major biotech firms, noting how investors are interpreting the results. Bristol Myers Squibb reported $11.5 billion in revenue f…
    BioPharma Dive · 5mo agoEarningsNeutral↗ source
  • Axsome receives FDA nod for Alzheimer’s agitation treatment
    Axsome announced that the U.S. Food and Drug Administration granted it a nod for a therapy aimed at agitation associated with Alzheimer’s disease, according to the STAT+ report. The decision marks…
    STAT · 5mo agoApprovalPositive↗ source
  • FDA drops Casey Means as surgeon general nominee, naming Fox News radiologist Nicole Saphier instead
    FDA withdrew the nomination of Casey Means for surgeon general and appointed Nicole Saphier, a radiologist and Fox News commentator. The switch underscores the administration’s limited sway in the…
    STAT · 5mo agoRegulatoryNegative↗ source
  • US fertility decline sparks debate over policy motives and family support
    The piece highlights growing alarm in the United States about a sustained drop in birth rates, pointing to factors such as costly childcare, unaffordable housing, shaky health‑care access, and the…
    STAT · 5mo agoNegative↗ source
  • J. Craig Venter, pioneering genomics scientist, dies at 79 after cancer treatment
    J. Craig Venter, a leading figure in genomics, passed away at age 79. The cause was complications from a cancer treatment. Venter’s work helped turn genetics from a craft into an industrial inform…
    STAT · 5mo agoPositive↗ source
  • Trump withdraws Casey Means as surgeon general nominee, names radiologist Nicole Saphier
    The Trump administration has withdrawn its nomination of Casey Means to serve as the next surgeon general. Means had been backed by the Make America Healthy Again movement, which sees the decision…
    STAT · 5mo agoNegative↗ source
  • EPA proposes first rule to flag microplastics and pharmaceuticals in drinking water, alongside $144 million ARPA-H study program
    The Environmental Protection Agency announced a proposed rule that would formally label microplastics and pharmaceutical residues in drinking water as contaminants that merit federal study and trac…
    STAT · 5mo agoRegulatoryNeutral↗ source
  • FDA greenlights Motif Neurotech's feasibility trial of brain-implant hat for treatment-resistant depression
    The U.S. Food and Drug Administration has approved Motif Neurotech's request to begin an initial feasibility trial of its brain‑implant device aimed at patients with treatment‑resistant depression.…
    STAT · 5mo agoCRLPositive↗ source
  • CDC-funded hepatitis B vaccine trial in Guinea-Bissau paused amid ethical concerns
    The U.S. Centers for Disease Control and Prevention awarded a $1.6 million grant to a Danish research group to compare hepatitis B vaccination at birth versus at six weeks in infants from Guinea‑Bi…
    STAT · 5mo agoRegulatoryNegative↗ source
  • CDC flu research pioneer Nancy Cox dies at 77
    Nancy Cox, a longtime CDC veteran, passed away at age 77 after battling glioblastoma, a form of brain cancer. Cox led the agency's influenza division for 22 years, expanding the team from a modest…
    STAT · 6mo agoNeutral↗ source
  • Tenpoint Therapeutics appoints Stephen Lane as chief medical officer
    STAT+ columnist Ed Silverman highlights recent personnel moves in the pharma sector. This week’s note focuses on a new senior appointment at Tenpoint Therapeutics. The company has hired Stephen La…
    STAT · 6mo agoNeutral↗ source
  • Merck commits up to $1 billion to Google Cloud partnership to accelerate AI across its operations
    Merck announced a multiyear partnership with Google Cloud, investing up to $1 billion to embed AI tools throughout its research, development, manufacturing, commercial and corporate functions. The…
    BioPharma Dive · 6mo agoDealPositive↗ source
  • Biotech layoff tracker 2026 shows Clinuvel cuts 20% staff, Novartis sheds 322 US jobs
    Fierce Biotech released its fifth annual layoff tracker for 2026, noting that workforce reductions continue to rise in the sector after a year of increasing cuts. The July update lists two compani…
    Fierce Biotech · 10mo agoLayoffsNegative↗ source
  • Biotech fundraising tracker reports $70M Series C for Ratio Therapeutics and $130M Series B for Crystalys Therapeutics
    The Fierce Biotech Fundraising Tracker continues to log only large venture capital rounds, focusing on deals of $50 million or more. Ratio Therapeutics secured a $70 million Series C, backed by in…
    Fierce Biotech · 10mo agoDealNeutral↗ source